These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 35235159)

  • 41. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. COVID-19 vaccine development and a potential nanomaterial path forward.
    Shin MD; Shukla S; Chung YH; Beiss V; Chan SK; Ortega-Rivera OA; Wirth DM; Chen A; Sack M; Pokorski JK; Steinmetz NF
    Nat Nanotechnol; 2020 Aug; 15(8):646-655. PubMed ID: 32669664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Advanced Materials for SARS-CoV-2 Vaccines.
    Mabrouk MT; Huang WC; Martinez-Sobrido L; Lovell JF
    Adv Mater; 2022 Mar; 34(12):e2107781. PubMed ID: 34894000
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World.
    Jhaveri R
    Clin Ther; 2021 Apr; 43(4):702-710. PubMed ID: 33832783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. COVID-19 Vaccines-All You Want to Know.
    Shishido AA; Barnes AH; Narayanan S; Chua JV
    Semin Respir Crit Care Med; 2023 Feb; 44(1):143-172. PubMed ID: 36646092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
    Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
    Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines.
    Ghasemiyeh P; Mohammadi-Samani S; Firouzabadi N; Dehshahri A; Vazin A
    Int Immunopharmacol; 2021 Nov; 100():108162. PubMed ID: 34562844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Next-generation COVID-19 vaccines: Opportunities for vaccine development and challenges in tackling COVID-19.
    Li Q; Wang J; Tang Y; Lu H
    Drug Discov Ther; 2021; 15(3):118-123. PubMed ID: 34234059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19.
    Bhattacharjee A; Saha M; Halder A; Debnath A; Mukherjee O
    Curr Microbiol; 2021 Feb; 78(2):435-448. PubMed ID: 33392670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).
    Alagheband Bahrami A; Azargoonjahromi A; Sadraei S; Aarabi A; Payandeh Z; Rajabibazl M
    Cell Mol Biol Lett; 2022 May; 27(1):38. PubMed ID: 35562685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential SARS-CoV-2 vaccines: Concept, progress, and challenges.
    Hosseini SA; Zahedipour F; Mirzaei H; Kazemi Oskuee R
    Int Immunopharmacol; 2021 Aug; 97():107622. PubMed ID: 33895475
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The COVID-19 pandemic: viral variants and vaccine efficacy.
    Ciotti M; Ciccozzi M; Pieri M; Bernardini S
    Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2.
    Lee KM; Lin SJ; Wu CJ; Kuo RL
    Biomed J; 2023 Feb; 46(1):70-80. PubMed ID: 36642222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs.
    Mossadeq S; Shah R; Shah V; Bagul M
    AAPS PharmSciTech; 2022 Nov; 24(1):2. PubMed ID: 36416999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and Efficacy of Different Therapeutic Interventions on Prevention and Treatment of COVID-19.
    Gyanwali P; Sharma S; Pant S; Koirala P; Adhikari K; Koirala J; Dhimal M
    J Nepal Health Res Counc; 2020 Sep; 18(2):151-158. PubMed ID: 32969369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine against COVID-19, Day to Save the Life.
    Ray SK; Mukherjee S
    Recent Pat Biotechnol; 2022; 16(1):2-5. PubMed ID: 34886784
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.
    Mirzaei R; Mohammadzadeh R; Mahdavi F; Badrzadeh F; Kazemi S; Ebrahimi M; Soltani F; Kazemi S; Jeda AS; Darvishmotevalli M; Yousefimashouf R; Keyvani H; Karampoor S
    Int Immunopharmacol; 2020 Nov; 88():106928. PubMed ID: 32862110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.